Arrivent Biopharma Common Stock Performance
| AVBP Stock | 21.97 1.45 7.07% |
ArriVent BioPharma has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0154, which signifies not very significant fluctuations relative to the market. As returns on the market increase, ArriVent BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ArriVent BioPharma is expected to be smaller as well. ArriVent BioPharma Common right now shows a risk of 3.61%. Please confirm ArriVent BioPharma Common maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to decide if ArriVent BioPharma Common will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ArriVent BioPharma Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, ArriVent BioPharma may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Actual Historical Performance (%)
One Day Return (0.39) | Five Day Return 5.42 | Year To Date Return (1.73) | Ten Year Return 2.2 | All Time Return 2.2 |
1 | ArriVent BioPharma Reports Third Quarter 2025 Financial Results | 11/10/2025 |
2 | Lifesci Capital Analysts Lower Earnings Estimates for AVBP | 11/13/2025 |
| Begin Period Cash Flow | 150.4 M | |
| Total Cashflows From Investing Activities | -192.5 M |
ArriVent BioPharma Relative Risk vs. Return Landscape
If you would invest 2,058 in ArriVent BioPharma Common on October 15, 2025 and sell it today you would earn a total of 74.00 from holding ArriVent BioPharma Common or generate 3.6% return on investment over 90 days. ArriVent BioPharma Common is currently generating 0.1207% in daily expected returns and assumes 3.6091% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than ArriVent, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ArriVent BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ArriVent BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ArriVent BioPharma Common, and traders can use it to determine the average amount a ArriVent BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0334
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | AVBP | Huge Risk |
| Negative Returns |
Based on monthly moving average ArriVent BioPharma is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ArriVent BioPharma by adding it to a well-diversified portfolio.
ArriVent BioPharma Fundamentals Growth
ArriVent Stock prices reflect investors' perceptions of the future prospects and financial health of ArriVent BioPharma, and ArriVent BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ArriVent Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 546.88 M | ||||
| Shares Outstanding | 41.28 M | ||||
| Price To Book | 2.78 X | ||||
| EBITDA | (80.49 M) | ||||
| Net Income | (80.49 M) | ||||
| Total Debt | 176 K | ||||
| Book Value Per Share | 7.47 X | ||||
| Cash Flow From Operations | (70.21 M) | ||||
| Earnings Per Share | (4.15) X | ||||
| Market Capitalization | 847.09 M | ||||
| Total Asset | 274.94 M | ||||
| Retained Earnings | (238.33 M) | ||||
| Working Capital | 209.71 M | ||||
About ArriVent BioPharma Performance
Assessing ArriVent BioPharma's fundamental ratios provides investors with valuable insights into ArriVent BioPharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ArriVent BioPharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | (0.28) | (0.30) |
Things to note about ArriVent BioPharma Common performance evaluation
Checking the ongoing alerts about ArriVent BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ArriVent BioPharma Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ArriVent BioPharma had very high historical volatility over the last 90 days | |
| ArriVent BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma generates negative cash flow from operations | |
| ArriVent BioPharma has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
- Analyzing ArriVent BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ArriVent BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining ArriVent BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ArriVent BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ArriVent BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ArriVent BioPharma's stock. These opinions can provide insight into ArriVent BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.